You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Lilly’s tirzepatide claims head-to-head trial win against injectable

Eli Lilly’s investigational treatment tirzepatide has demonstrated superior A1C and body weight reduction compared to injectable semaglutide in adults with type 2 diabetes.